Reservoirs, Sanctuaries, and Residual Disease: The Hiding Spots of HIV-1

REFERENCES

• O'Brien W, Pomerantz RJ. AIDS and other diseases due to HIV infection. In: Neal Nathanson N, ed. Viral Pathogenesis. New York: Raven Press; 1997:813–837.
   Google Scholar
• Mellors J, Rinaldo C, Gupta P, et al. Prognosis in HIV infection predicted by the quantity of virus in plasma. Sci-ence. 1996;272:1167–1170.
   PubMed Web of Science ®Google Scholar
• Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by com-petitive PCR. Science. 1993;259:1749–1754.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Levy JA. HIV-1 and the Pathogenesis of AIDS. Washington, DC: ASM Press; 1998.
   Google Scholar
• Bruggeman LA, Rose MD, Tanji N, et al. The kidney is a previously unrecognized reservoir for HIV-1 replication. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 161.
   Google Scholar
• Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:357–362.
   Web of Science ®Google Scholar
• Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61:213–222.
   PubMed Web of Science ®Google Scholar
• Bukrinsky NU, Stanwick TL, Dempsey MP, et al. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 1991;254:423–427.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Essunger P, Cao Y, et al. Decay characteris-tics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188.
   PubMed Web of Science ®Google Scholar
• Chun TWL, Carruth D, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188.
   PubMed Web of Science ®Google Scholar
• Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295.
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science. 1997;278:1295–1300.
   PubMed Web of Science ®Google Scholar
• Chun TW, Stuyver L, Mizell SB, et al. Presence of an induc-ible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci USA. 1997;94: 13193–13197.
   PubMed Web of Science ®Google Scholar
• Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reser-voir for human immunodeficiency virus type 1. J ViroL 2000;74:7824–7833.
   PubMed Web of Science ®Google Scholar
• Chun TW, Engle D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869–8873.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Engel D, Mizeh SB, et al. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combi-nation of cytokines. J Exp Med. 1998;188:83–91.
   PubMed Web of Science ®Google Scholar
• Persaud D, Pierson T, Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4+ T-lymphocytes in infected chil-dren. J Clin Invest 2000;105:995–1003.
   PubMed Web of Science ®Google Scholar
• Brooks DG, Kitchen SG, Kitchen KMR, et al. Generation of HIV latency during thympoiesis. Nat Med. 2001;7: 459–464.
   PubMed Web of Science ®Google Scholar
• Gunthard HT, Wong JK, Ignacio CC, et al. Human immuno-deficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent anti-retroviral therapy. J ViroL 1998;72:2422–2428.
   PubMed Web of Science ®Google Scholar
• Sanchez G, Xu X, Chermann JC, et al. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected indi-viduals. J ViroL 1997;71:2233–2240.
   PubMed Web of Science ®Google Scholar
• Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS. 200115: 17–22.
   Google Scholar
• Veazey RS, DeMaria MA, Chalifoux LV, et al. Gastrointesti-nal tract as a major site of CD4+ T-cell depletion and viral replication in SIV infection. Science. 1998;280:427–443.
   PubMed Web of Science ®Google Scholar
• Pomerantz RJ, Kuritzkes DR, de la Monte SM, et al. Infection of the retina by human immunodeficiency virus type 1. N Engl J Med. 1987;317:1643–1647.
   PubMed Web of Science ®Google Scholar
• Zhang H, Dornadula G, Beumont M, et al. HIV-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med. 1998;339:1803–1809.
   PubMed Web of Science ®Google Scholar
• Gunthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospi-nal fluid after suppression of viremia for 2 years. J Infect Dis. 2001183: 1318–1327.
   Google Scholar
• Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000;14:237–242.
   PubMed Web of Science ®Google Scholar
• Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of H IV-1 infection. Science. 1997;276:960–964.
   PubMed Web of Science ®Google Scholar
• Taylor S, Back DJ, Workman J, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS. 1999;13:859–872.
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen. J Infect Dis. 2000;181:1622–1628.
   PubMed Web of Science ®Google Scholar
• Barroso PF, Schechter M, Gupta P, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med. 2000;133:280–284.
   PubMed Web of Science ®Google Scholar
• Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415–421.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605–1613.
   PubMed Web of Science ®Google Scholar
• Gunthard HF, Frost SDW, Leigh-Brown J, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J ViroL 1999;73:9404–9412.
   PubMed Web of Science ®Google Scholar
• Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614–1622.
   PubMed Web of Science ®Google Scholar
• Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med. 1999;6:76–81.
   Web of Science ®Google Scholar
• Dornadula G, Nunnari G, VaneIla M, et al. Human immuno-deficiency virus type 1-infected persons with residual dis-ease and viral reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant viro-logic and immunologic subgroups. J Infect Dis. 2001183:1682–1687.
   Google Scholar
• Pomerantz RJ, Trono D, Feinberg MB, et al. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency. Cell. 1990;61:1271–1276.
   PubMed Web of Science ®Google Scholar
• Zhang Z-Q, Schuler T, Zupancic M, et al. Sexual transmis-sion and propagation of SIV and HIV in resting and acti-vated CD4+ T cells. Science. 1999;286:1353–1357.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59–F62.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Davey RT, Ostrowsi M, et al. Relationship be-tween pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000;6:757–761.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chung C, Hu B-S, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active anti-retroviral therapy. J Clin Invest. 2000;106:839–845.
   PubMed Web of Science ®Google Scholar
• Dornadula G, Zhang H, Van Uitert B, et al. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART). JAMA. 1999;282:1627–1632.
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano, JS, et al. Latent infection of CD4+ T-cells provides a mechanism for lifelong persis-tence of HIV-1 even in patients on effective combination therapy. Nat Med. 1999;5:512–517.
   PubMed Web of Science ®Google Scholar
• Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 1999;6:82–85.
   Web of Science ®Google Scholar
• Haylir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171–179.
   PubMed Web of Science ®Google Scholar
• Ward D, Sklar P. The significance of low-level viremia in patients with previously "undetectable" HIV-1 RNA levels. In: Program and abstracts of the XIII International Confer-ence on AIDS; July 9–14, 2000; Durban, South Africa. Abstract M0PpB1019.
   Google Scholar
• Easterbrook P, Ives N, Peters B, et al. The natural history and clinical significance of intermittent virological "blips" in patients who attain an initially undetectable viral load (VL) on HAART. In: Program and abstracts of the XIII Interna-tional Conference on AIDS; July 9–14, 2000; Durban, South Africa. Abstract WeOrB610.
   Google Scholar
• Hlavacek WS, Wofsy C, Perelson AS. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sc/ USA. 1999;96:14681–14686.
   PubMed Web of Science ®Google Scholar
• Berger EA, Moss B, Pastan I. Reconsidering targeted tox-ins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci USA. 1998;95:11511–11513.
   PubMed Web of Science ®Google Scholar
• Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulatory therapy for HIV-1 reservoirs in infected indi-viduals on virally-suppressive HAART. J Infect Dis. In press.
   PubMed Web of Science ®Google Scholar